Share
2,101 Posts.
lightbulb Created with Sketch. 218
clock Created with Sketch. 15/04/15
09:46
Share
Originally posted by thecouncilgritter
↑
Do you have a Masters Degree in Pettifoggery or is it just a natural trait? I didn't intend to respond in detail to your insulting response to my "flawed" general comments but I will offer a few small rejoinders. As a man/woman with a keen analytic bent, I take it that you have contacted the company to validate your observations? It would be the ultimate in arrogance NOT to speak with senior management of a company before making such a sweeping denigration of the deal publicly.Based on this, as well as assuming historical rate of cash burn continues and that the exchange rate remains unchanged at its current level, the company has enough cash until around this time next year. Also, I can’t see how it validates the Osiris deal at all, as you suggest. All this deal does is give Celgene an exclusive right to study MSB’s data related to GVHD (and also to bits of MSB’s portfolio that MSB itself had de-prioritised, namely disease fields in oncology, bowel inflammation and organic transplant rejection).
Expand
I think his point which was well understood was Celgene didn't really pay anything for this. They paid to purchase shares as part of the deal so yes it cost them. However that is a cost they are free to recoup and likely profit from at any time and they can sell on market.
(20min delay)